Skip to content

Quality Of LIfe Tool for IBD

Quality Of LIfe Tool for IBD (QOLITI): Pilot Testing of a Self-administered Intervention to Target Psychological Distress in Inflammatory Bowel Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02707068
Acronym
QOLITI
Enrollment
62
Registered
2016-03-14
Start date
2016-01-31
Completion date
2016-11-30
Last updated
2017-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Disease

Keywords

Quality of Life, Self-help intervention

Brief summary

This study seeks to test the feasibility of a self-management manual with minimal telephone support by a healthcare professional. The study will also explore the acceptability of the intervention manual to patients.

Detailed description

Psychological distress and poor quality of life are common in Long Term Conditions (LTCs) including Inflammatory Bowel Disease (IBD). Rates of depression are 11-21% in people with IBD (pwIBD) with high levels of anxiety in 41%. Additionally, as diagnosis typically occurs at 15-40 years, educational and employment attainment can be effected and symptoms and medical procedures such as diarrhoea and colonoscopies can be stressful and embarrassing. The relapsing and remitting nature can also cause uncertainty and fear of social integration. Most of the psychosocial literature in IBD has focused on the potential impact of stress and recording the prevalence and non-modifiable predictors of depression and anxiety such as active disease, hospitalisation, surgery (particularly stoma formation) and unemployment. Less research in IBD has investigated potentially modifiable factors known to be related to distress and quality of life in other LTCs such as illness perceptions, social support and coping strategies, although one study has found a similar association in IBD. This is of particular interest due to the potential behavioural and physiological pathways through which they could impact on health and quality of life. Psychosocial interventions in IBD to date have focused on stress management or Cognitive Behavioural Therapy (CBT) to reduce distress and improve quality of life. Although small sample studies have shown small to moderate benefits of the interventions, these approaches are time consuming and resource intensive such as group or individual therapy. This can result in low adherence and retention due to the required time commitment, but more importantly are not widely applicable in the NHS due to limited available expertise and in particular, their cost. Psychological interventions are most effective when tailored specifically to disease-related factors and the patients' developmental stage. Such interventions are currently lacking for IBD. An alternative to therapist-led intervention is to promote self-management through paper or online self-help interventions supplemented by minimal guided support by a health care professional. This type of supported, self-directed intervention is cost-effective and has shown strongest results when targeted to the needs of specific diseases. There is currently no similar self-directed manual for IBD available. This type of supported, self-directed intervention can be incorporated into standard care where required, is cost-effective and has the potential to support pwIBD to successfully adjust to their LTC for better clinical and quality of life outcomes. Although most people will not require intensive psychological therapy for debilitating distress, structured support to adjust to the many demands that IBD places on people could help to bridge the gap for the 40-50% of pwIBD that show moderate levels of distress, improving their quality of life and management of the illness. Sample size justification: A sample size of 30 per group is in line with recommendations for pilot studies where the aim is to determine the feasibility of a future efficacy study by estimating the treatment effect (for a power calculation) and estimating rate of non-completion of the intervention. A minimum total sample size of 50 (i.e. 25 per group) is recommended to allow for a precise estimate of the pooled standard deviation at the post intervention assessment. Increasing the number to 30 per group allows for non-completion of up to 20%. Furthermore, a sample size of 30 per group allows for an acceptably precise estimate of the non-completion rate; a 95% confidence interval less than +/-11% for completion rates of 80% or higher. Adults (\>18 years) with IBD will be provided with an information sheet and invited to participate in the study. Following informed consent and the completion of baseline questionnaires, participants will be randomised to receive either intervention + treatment as usual (treatment group) or treatment as usual (control group). Randomisation will be completed by King's College London Clinical Trials Unit independently of the research team so that the researchers remain blind to condition. As recommended for a pilot or feasibility study, results will be mainly descriptive and will include; proportion of eligible people; consent rate; retention rate. The investigators plan on using an intention-to-treat regression analysis and include the pre measure as a covariate. This data will allow for effect sizes and feasibility to be determined in order to adequately power a full trial of the intervention in a follow-up study. Thematic analysis of the qualitative feedback data will be conducted by a member independent of the research team.

Interventions

BEHAVIORALQuality Of LIfe Tool for IBD (QOLITI)

The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.

Sponsors

Guy's and St Thomas' NHS Foundation Trust
CollaboratorOTHER
King's College London
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants with must have a diagnosis of IBD, * be over 18 years of age as well as able to read and understand English fluently. * Informed consent must be obtained.

Exclusion criteria

* Participants are not eligible for the study, if they do not fulfil the inclusion criteria. * Suicidal patients will be directly referred to liaison psychiatry or their GP and will not be able to access the study as the intensity of the manual intervention is within the low-moderate range and thus not suitable to address severe symptoms appropriately.

Design outcomes

Primary

MeasureTime frameDescription
Effectiveness: Change in Inflammatory Bowel Disease - specific quality of lifewithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether IBD-specific quality of life levels have changed from pre- to post-intervention (Inflammatory Bowel Disease Questionnaire, IBDQ)
Effectiveness: Change in depressionwithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether depression levels have changed from pre- to post-intervention (Patient Health Questionnaire, PHQ-9)
Acceptability: Change in numbers of participants throughout the trial2 weeks of obtaining consent compared to 10 weeks post-randomisationPercentage of consenting eligible participants retained until completion
Effectiveness: Change in anxietywithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether anxiety levels have changed from pre- to post-intervention (Generalised Anxiety Disorder 7-item scale, GAD-7)
Effectiveness: Change in generic quality of lifewithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether generic quality of life levels have changed from pre- to post-intervention (EQ-5D-5L)
Feasibilitywithin 2 weeks of potential participants getting in touch (i.e. once at the beginning of the study)Percentage of patients eligible
Acceptabilitywithin 2 weeks of potential participants getting in touch (i.e. once at the beginning of the study)Percentage of eligible patients consenting

Secondary

MeasureTime frameDescription
Change in fatiguewithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether fatigue levels have changed from pre- to post-intervention (Chalder Fatigue Scale, CFS)
Change in illness perceptionwithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether illness perception has changed from pre- to post-intervention (Illness Perception Questionnaire, IPQ-R)
Change in disease activitywithin 2 weeks of obtaining consent as well as 10 weeks post-randomisationAssessing whether subjective levels if disease activity have changed from pre- to post-intervention (patient-modified Simple Clinical Colitis Activity Index, p-SCCAI)
Semi-structured qualitative interviewsat 12 weeks post-randomisationsemi-structured qualitative interviews of up to 30 minutes to obtain retrospective appraisal of the intervention (i.e. content and layout), conducted by a person independent of the research group, transcribed data will be analysed based on principles of grounded theory

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026